Company: GIFLF
Filing Date: 2025-02-26
Form Type: 6-K
Source: 0001104659-25-017501
Chunk: 18

Company: Grifols SA
Filing Date: 2025-02-26
Form: 6-K
Chunk 18
---
 science - based emissions reductions targets conform with the SBTi Criteria and Recommendations. Climate Risk and Opportunities assessment A climate risk and opportunity assessment has been conducted in alignment with key frameworks and recommendations (CSRD, TCFD, etc.) Total Activities 30+ Electricity consumption 44,6% renewables (+30%) Of total electricity consumption 2023 Committed to consume 100% renewable electricity by 2030

- 26 - Q4 2024 Results Sustainability | Progress in 2024 Ethical Leadership is in Our DNA Introductory Remarks Business Performance Financials Final remarks Annex ESG Supply Chain Risk Assessment to mitigating Supplier Key Risks and Impacts Responsible Supply Chain Incorporation of an ESG & Risk Management Specialist into the Global Procurement Department ESG R atings Grifols ranked nº 1 biotech company in Dow Jones Sustainability Indices Grifols on the S&P Global Sustainability Yearbook 2025 Incentive plans including ESG criteria Annual incentive plan for the entire workforce And a long - term incentive plan + ESG R atings Grifols has been awarded for a second year with the Gold Medal by EcoVadis 2025 Industry ESG top rated according to Sustainalytics

- 27 - Q4 2024 Results ANNEX Financials

- 28 - Q4 2024 Results Revenue | Q4 2024 Introductory Remarks Business Performance Financials Final remarks Annex Q4 2024 Q4 2023 In thousands of euros Reported At cc* Revenue by Business Unit 1,975,814 1,769,550 11.7% 13.6% Biopharma 1,687,487 1,492,423 13.1% 15.1% Diagnostic 166,063 172,498 (3.7%) (2.0%) Bio Supplies 52,404 41,285 26.9% 29.0% Others & intersegments 69,860 63,344 10.3% 11.2% Revenue by Country 1,975,814 1,769,550 11.7% 13.6% US + CANADA 1,079,798 1,005,889 7.3% 9.7% EU 431,668 338,972 27.3% 27.4% ROW 464,348 424,689 9.3% 11.9% * Constant